{"id": "179635", "url": "https://fevir.net/resources/Evidence/179635", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/comparative-participant-flow-evidence"], "versionId": "7", "lastUpdated": "2024-12-13T21:07:33.593Z"}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\" xml:lang=\"en\" lang=\"en\"><p>[No data.]</p></div>", "status": "empty"}, "title": "ComparativeParticipantFlowEvidence: Dropout due to stopping intervention Lofexidine vs. Placebo in opioid detoxification trial", "author": [{"name": "Brian S. Alper"}], "citeAs": "ComparativeParticipantFlowEvidence: Dropout due to stopping intervention Lofexidine vs. Placebo in opioid detoxification trial [Database Entry: FHIR Evidence Resource]. Contributors: Brian S. Alper [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 179635. Revised 2024-05-16. Available at: https://fevir.net/resources/Evidence/179635. Computable resource at: https://fevir.net/resources/Evidence/179635#json.", "status": "active", "contact": [{"telecom": [{"value": "support@computablepublishing.com", "system": "email"}]}], "copyright": "https://creativecommons.org/licenses/by-nc-sa/4.0/", "extension": [{"url": "http://hl7.org/fhir/uv/ebm/StructureDefinition/artifact-publication-status", "valueCodeableConcept": {"coding": [{"code": "active", "system": "http://terminology.hl7.org/CodeSystem/cited-artifact-status-type", "display": "Active"}]}}], "publisher": "Computable Publishing LLC", "relatesTo": [{"type": "derived-from", "targetReference": {"type": "Citation", "display": "18508207 A Phase 3 placebo-controlled, double-blind, multi-site trial of the alpha-2-adrenergic agonist, lofexidine, for opioid withdrawal", "reference": "Citation/179637"}}], "statistic": [{"quantity": {"value": 1.59}, "sampleSize": {"numberOfParticipants": 68}, "description": "18/33 (54.5%) with Lofexidine vs. 12/35 (34.3%) with Placebo (relative risk 1.59, p < 0.01)", "statisticType": {"coding": [{"code": "STATO:0000245", "system": "https://fevir.net/sevco", "display": "Risk Ratio"}]}, "numberAffected": 30, "attributeEstimate": [{"type": {"coding": [{"code": "STATO:0000700", "system": "https://fevir.net/sevco", "display": "p-value"}]}, "quantity": {"value": 0.01, "comparator": "<"}, "description": "p < 0.01"}]}], "identifier": [{"type": {"text": "FEvIR Object Identifier", "coding": [{"system": "http://terminology.hl7.org/CodeSystem/v2-0203", "code": "ACSN", "display": "Accession ID"}]}, "value": "179635", "system": "https://fevir.net/FOI", "assigner": {"display": "Computable Publishing LLC"}}], "useContext": [{"code": {"code": "evidence-communication", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Evidence Communication"}, "valueCodeableConcept": {"coding": [{"code": "ComparativeParticipantFlowEvidence", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "ComparativeParticipantFlowEvidence"}]}}], "description": "Dropout due to stopping intervention 18/33 with Lofexidine vs. 12/35 with Placebo in opioid detoxification trial", "resourceType": "Evidence", "variableDefinition": [{"description": "Participants in the opioid detoxification trial", "variableRole": "population"}, {"description": "GroupAssignment: Lofexidine vs. Placebo", "variableRole": "exposure", "comparatorCategory": "false"}, {"observed": {"type": "EvidenceVariable", "display": "PartiicipantFlowMeasure: Dropout due to stopping intervention", "reference": "EvidenceVariable/179636"}, "description": "Dropout due to stopping intervention", "variableRole": "outcome"}], "name": "ComparativeParticipantFlowEvidence_Dropout_due_to_stopping_intervention_Lofexidine_vs_Placebo_in_opioid_detoxification_trial"}